Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific / administration & dosage
  • Antibodies, Bispecific / adverse effects
  • Antibodies, Bispecific / drug effects*
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Combined Modality Therapy
  • Consolidation Chemotherapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Oncogene Proteins, Fusion / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents, Immunological
  • Oncogene Proteins, Fusion
  • TCF3-HLF fusion protein, human
  • blinatumomab